1. NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear–mitochondrial crosstalk in ERCC1-deficient populations. (December 2016) Authors: Touat, M.; Olaussen, K.; Sourisseau, T.; Friboulet, L.; Dorvault, N.; Enot, D.; Bigot, L.; Pontoizeau, C.; Mardakheh, F.; Thompson, A.; Bouillaud, F.; Ricchetti, M.; Ottolenghi, C.; Pierron, G.; Sarasin, A.; Lombès, A.; Ashworth, A.; Lord, C.; Soria, J.C.; Postel-Vinay, S. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SP-0258: Potentiation of anti-tumor immune effects by PARP Inhibitors. (November 2020) Authors: Chabanon, R.; Muirhead, G.; Krastev, D.; Adam, J.; Garrido, M.; Morel, D.; Dorvault, N.; Pettitt, S.; Tutt, A.N.J.; Marabelle, A.; Soria, J.C.; Lord, C.J.; Postel-Vinay, S. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗